Merck KGaA (FRA:MRK) received a €109.00 ($128.24) price target from equities researchers at Commerzbank Ag in a research report issued on Wednesday, August 9th. The brokerage currently has a “neutral” rating on the healthcare company’s stock.
A number of other equities analysts have also recently weighed in on the company. equinet AG set a €112.00 ($131.76) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Monday, June 26th. Nord/LB reissued a “neutral” rating on shares of Merck KGaA in a report on Wednesday, June 28th. Warburg Research set a €116.00 ($136.47) price objective on Merck KGaA and gave the company a “neutral” rating in a report on Friday, July 7th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Merck KGaA in a research note on Monday, May 8th. Finally, Deutsche Bank AG set a €125.00 ($147.06) price target on Merck KGaA and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. Sixteen analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of €108.48 ($127.62).
Shares of Merck KGaA (FRA MRK) opened at 91.245 on Wednesday. Merck KGaA has a one year low of €89.00 and a one year high of €115.00. The company has a 50-day moving average price of €97.65 and a 200 day moving average price of €103.53. The company has a market capitalization of €39.67 billion and a PE ratio of 23.786.
About Merck KGaA
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.